Order results by:
| Issue | Title | |
| Vol 10, No 2 (2017) | COSTS OF ANTIRETROVIRAL DRUGS USED IN THE THERAPY OF HIV-INFECTED PATIENTS: A PHARMACOECONOMIC ANALYSIS | Abstract similar documents |
| M. B. Kubaeva, Y. Sh. Guchshina | ||
| "... The aim of our study was to conduct a pharmacoeconomic and cost analysis of the therapeutic use ..." | ||
| Vol 5, No 1 (2012) | COST OF ILLNESS ANALYSIS: TYPES, METHODOLOGY, RUSSIAN SPECIFICS | Abstract similar documents |
| R. I. Yagudina, I. Yu. Zinchuk, M. M. Litvinenko | ||
| "... Cost of illness is one of the basic methods of pharmacoeconomical estimation and in substance ..." | ||
| Vol 13, No 4 (2020) | The social-economic burden of spinal muscular atrophy in Russia | Abstract similar documents |
| A. S. Kolbin, D. V. Vlodavets, A. A. Kurylev, Yu. Ye. Balykina, M. A. Proskurin, S. A. Mishinova, O. Yu. Germanenko, N. Yu. Kolbina | ||
| "... (medical, social etc.) throughout their life and the cost of the care has never been calculated in Russia ..." | ||
| Vol 5, No 3 (2012) | PHARMACOECONOMIC EVALUATION OF THE MEDICINAL PRODUCTS ERLOTINIB, DOCETAXEL, PEMETREXED AND GEFITINIB IN THE SECOND-LINE TREATMENT OF LOCALLY-ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER | Abstract similar documents |
| A. U. Kulikov | ||
| "... химиотерапии 1-й линии проводят 2-ю линию лечения НМРЛ. В качестве препаратов 2-й линии монотерапии НМРЛ ..." | ||
| Vol 17, No 4 (2024) | Development of a classification of anesthetic management methods and protocols for calculating financial costs | Abstract similar documents |
| D. V. Lukyantseva, J. A. Agafonova, V. V. Omelyanovskiy, S. A. Kovaleva, D. V. Fedyaev, I. N. Pasechnik, V. V. Schukin, D. S. Blinov, A. B. Abrosimov | ||
| "... Background. The costs of anesthetic support represent a significant and essential component ..." | ||
| Vol 10, No 4 (2017) | PHARMACOECONOMIC JUSTIFICATION OF A WIDER USE OF PREVENTIVE HEMOPHILIA THERAPY IN THE RUSSIAN FEDERATION | Abstract similar documents |
| M. Yu. Frolov, V. A. Rogov | ||
| "... simulated. Based on this mathematical model, the treatment outcomes, the costs of outpatient, hospital ..." | ||
| Vol 6, No 4 (2013) | Pharmacoeconomical assessment of сerebrolysin in the treatment of the acute disturbances of cerebral circulation | Abstract similar documents |
| A. Yu. Kulikov, L. A. Komarov | ||
| "... of approaches to treatment policy of this group of patients. We performed cost-effectiveness analysis ..." | ||
| Vol 10, No 2 (2017) | ECONOMIC ASSESSMENT OF THE EFFECTIVENESS AND SAFETY OF THE COMMONLY PRACTICED PERIOPERATIVE ANTIBIOTIC PROPHYLAXIS (BASED ON AN EARLIER EPIDEMIOLOGICAL SURVEY OF MULTIDISCIPLINARY HOSPITALS) | Abstract similar documents |
| Yu. M. Gomon, A. S. Kolbin, S. V. Sidorenko, A. M. Kuzhel’, A. V. Repina, Yu. V. Lobzin, Yu. E. Balykina | ||
| "... approved for national clinical practice. Aim. To perform a cost-effectiveness analysis of the commonly ..." | ||
| Vol 5, No 1 (2012) | PHA RMA COE CONOMI CAL EVALUATION OF MULTIPLE MYELOMA TREATMENT WITH REVLIMID (LENALIDOMIDE ) IN THE RUSSIAN FEDE RATION | Abstract similar documents |
| R. Yagudina, A. Kulikov, B. Misikova | ||
| Vol 7, No 1 (2014) | ECONOMIC ASSESSMENT OF MAGNESIUM DEFICIENCY CORRECTION FOR BASIC THERAPY EFFICACY OF UNCONTROLLED ASTHMA IN CHILDREN | Abstract similar documents |
| V. I. Petrov, I. N. Shishimorov, O. V. Magnitskaya, Ju. V. Ponomareva | ||
| "... the cost of achieving control and cost per symptom-free day after 12 and 24 weeks of therapy ..." | ||
| Vol 14, No 3 (2021) | Pharmacoeconomic evaluation of the effectiveness of therapy for metastatic colorectal cancer | Abstract similar documents |
| Yu. Yu. Petukhova, E. V. Eliseeva, M. V. Volkov, O. N. Li, A. G. Petukhova | ||
| "... with this disease. Material and methods. The authors performed a comparative cost-effectiveness analysis ..." | ||
| Vol 9, No 1 (2016) | COMPARATIVE CLINICAL AND ECONOMIC ANALYSIS OF THE INTENSIFICATION THERAPY IN PATIENTS WITH UNCONTROLLED DIABETES TYPE 2 USING BASAL INSULIN OR DAPAGLIFLOZIN | Abstract similar documents |
| V. I. Petrov, S. V. Nedogoda, M. Yu. Frolov, A. S. Salasyuk, I. N. Barykina, V. O. Smirnova, V. Yu. Khripaeva | ||
| "... according to standard pharmacoeconomic methods: cost-utility analysis (CUA), budget impact analysis (BIA ..." | ||
| Vol 11, No 2 (2018) | Economic evaluation of postoperative hypofractionated radiation therapy in patients with breast cancer | Abstract similar documents |
| G. V. Afonin, Yu. A. Ragulin, M. V. Avxentyeva, I. A. Gulidov, S. A. Ivanov, A. D. Kaprin | ||
| "... the treatment costs in patients with breast cancer while maintaining a high treatment efficacy and quality ..." | ||
| Vol 13, No 4 (2020) | Evaluation of the economic effect of biological therapy in patients with severe COVID-19 and cytokine storm | Abstract similar documents |
| M. Yu. Frolov, A. S. Salasyuk, V. A. Rogov | ||
| "... using the cost of illness analysis in a model developed in Microsoft Excel 2016 (Microsoft, USA ..." | ||
| Vol 6, No 2 (2013) | FIRST RUSSIAN TYPE 2 DIABETES MELLITUS SIMULATION MODEL WITH DISCREET EVENTS MODELING. HEALTH-ECONOMIC ANALYSIS | Abstract similar documents |
| A. S. Kolbin, O. K. Khmelnitskiy, A. A. Kurylev, Yu. E. Balykina, M. A. Proskurin, E. P. Kolpak, M. V. Bure | ||
| "... .). Cost-effectiveness analysis was performed. Results: The developed model allows to assess the risk ..." | ||
| Vol 12, No 4 (2019) | Comparative clinical and economic analysis of using SYSADOA drugs containing chondroitin sulphate or influencing its biosynthesis in the treatment of patients with stage II knee osteoarthritis | Abstract similar documents |
| I. V. Sarvilina, A. N. Galustyan, A. K. Hadzhidis, I. S. Sardaryan, N. V. Lavrov, O. A. Gromova, Yu. S. Prokofieva | ||
| "... & Lawrence classification. We calculated the cost-effectiveness from the direct costs and treatment ..." | ||
| Vol 18, No 1 (2025) | Pharmacoeconomic analysis of lanreotide and prolonged-release octreotide in first- and second-line therapy of acromegaly | Abstract similar documents |
| I. S. Krysanov, E. V. Makarova, V. Yu. Ermakova, D. V. Kurkin | ||
| "... for discussion. Despite the higher cost of lanreotide compared to octreotide, the former may have an advantage ..." | ||
| Vol 15, No 1 (2022) | The real practice of clinical and economic research of drugs included in the Federal Program of High-Cost Nosologies | Abstract similar documents |
| A. S. Kolbin, Yu. M. Gomon, A. R. Kasimova, A. A. Kurylev, A. E. Bem | ||
| "... in the Federal Program of High-Cost Nosologies (HCN). Material and methods. In the CyberLeninka and eLibrary ..." | ||
| Vol 14, No 3 (2021) | Health economic evaluation of risdiplam in patients with spinal muscular atrophy | Abstract similar documents |
| А. S. Kolbin, А. А. Kurylev, Yu. Е. Balykina, М. А. Proskurin, S. А. Mishinova | ||
| "... Russian regulation. Cost-minimization analysis was used. We accounted for direct medical costs ..." | ||
| Vol 14, No 2 (2021) | Organizational and economic aspects of triplet therapy of relapsed/refractory multiple myeloma in the Russian healthcare setting | Abstract similar documents |
| E. A. Pyadushkina, E. V. Derkach, V. I. Ignatyeva, E. E. Yagnenkova, T. Yu. Klitochenko, T. V. Shelekhova, A. N. Levanov | ||
| "... these expensive options can be financially secured remains open. Objective: to assess the cost of triplets ..." | ||
| Vol 6, No 2 (2013) | COST-EFFECTIVENESS ANALYSIS OVER USE OF TYROSINE KINASE INHIBITORS (TASIGNA AND GLEEVEC) FOR TREATMENT OF CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE AS FIRST-LINE THERAPY FOR DE NOVO PATIENTS | Abstract similar documents |
| R. I. Yagudina, A. Yu. Kulikov, I. A. Komarov | ||
| "... performed cost-effectiveness analysis on the basis of two tyrosine kinase inhibitors in Russian Federation ..." | ||
| Vol 6, No 2 (2013) | PHARMACOECONOMIC STUDY OF PRIMARY OPEN-ANGLE GLAUCOMA TREATMENT WITH CARBONIC ANHYDRASE INHIBITORS | Abstract similar documents |
| A. Yu. Kulikov, V. G. Serpik | ||
| "... with Dorzopt and Trusopt from cost-efficacy perspective and can be claimed dominant. Futhermore Azopt ..." | ||
| Vol 6, No 4 (2013) | Фармакоэкономический анализ использования лираглутида в составе комбинированной терапии в лечении сахарного диабета 2-го типа | Abstract similar documents |
| A. Yu. Kulikov, I. V. Novikov | ||
| "... The analysis goal is to determine the cost-effectiveness of liraglutideas add-on to metformin ..." | ||
| Vol 9, No 1 (2016) | PHARMACOECONOMIC STUDY OF LENVIMA (LENVATINIB) IN ADVANCED PROGRESSIVE RADIO IODINE REFRACTORY DIFFERENTIATED THYROID CANCER IN THE RUSSIAN FEDERATION | Abstract similar documents |
| M. Yu. Frolov, V. A. Rogov | ||
| "... radio iodine refractory differentiated thyroid cancer in the Russian Federation. Methods. Cost ..." | ||
| Vol 10, No 1 (2017) | EVALUATION OF DRUG THERAPY IN PROGRESSING DIFFERENTIATED THYROID CANCER REFRACTORY TO RADIOACTIVE IODINE IN PATIENTS RESIDING IN THE RUSSIAN FEDERATION : PHARMACOECONOMIC ASPECTS | Abstract similar documents |
| M. Yu. Frolov, V. A. Rogov | ||
| "... impact and the “cost-effectiveness” parameters were analyzed using the MS Excel-model based on a 3-year ..." | ||
| Vol 13, No 2 (2020) | Pharmacoeconomic analysis of tiotropium bromide and olodaterol fixed combination as maintenance therapy for patients with COPD in the Russian Federation | Abstract similar documents |
| S. V. Nedogoda, M. Yu. Frolov, A. S. Salasyuk, I. N. Barykina, V. O. Smirnova | ||
| "... was used for the estimation of direct medical costs associated with different medications. Costminimization ..." | ||
| Vol 10, No 4 (2017) | THE STATE GUARANTEES PROGRAM OF FREE MEDICAL CARE: APPROACHES TO STANDARDIZE THE COSTS OF MEDICAL CARE | Abstract similar documents |
| Yu. A. Ledovskikh, E. V. Semakova, M. V. Avksent’eva | ||
| "... this standard provides an opportunity for calculating the costs of implementing the SGP, the past experience ..." | ||
| Vol 12, No 4 (2019) | Pharmacoeconomic analysis of using cyclin-dependent kinase 4 and 6 inhibitors in the first line treatment of HR-positive HER2-negative advanced breast cancer | Abstract similar documents |
| N. A. Avxentyev, E. V. Lubennikova, M. Yu. Frolov | ||
| "... consisted of two parts: clinical and economic study and budget impact analysis. We used cost minimization ..." | ||
| Vol 16, No 3 (2023) | Efficacy of alectinib in comparison with lorlatinib in patients with ALK-positive non-small cell lung cancer: pharmacoeconomic study | Abstract similar documents |
| A. S. Kolbin, Yu. M. Gomon, M. A. Proskurin, Yu. E. Balykina | ||
| "... cancer (NSCLC). Materials and methods. The calculations included the direct costs of the healthcare ..." | ||
| Vol 5, No 3 (2012) | COST-UTILITY ANALYSIS PATIENTS WITH LOW BACK PAIN AFTER TREATMENT INTRAOSSEOUS BLOCKADES | Abstract similar documents |
| M. V. Yakovlev, A. U. Kulikov, E. L. Sokov, I. E. Kornilova | ||
| "... , myorelaxants, physical therapy). Measured direct costs at 1-year follow-up. Quality of life was measured ..." | ||
| Vol 11, No 1 (2018) | Pharmacoeconomic assessment of antipsychotic treatment in outpatients with schizophrenia | Abstract similar documents |
| I. A. Vilyum, B. V. Andreev, M. A. Proskurin, Yu. E. Balykina | ||
| "... in the clinical and economic analysis of these treatments. Direct and indirect costs were taken into account ..." | ||
| Vol 11, No 2 (2018) | Pharmacoeconomic analysis of using typical and atypical antipsychotics in schizophrenia | Abstract similar documents |
| I. A. Vilyum, B. V. Andreev, M. A. Proskurin, Yu. E. Balykina | ||
| "... ’ medical records. The cost-effectiveness analysis, incremental analysis, and «budget impact» analysis were ..." | ||
| Vol 16, No 3 (2023) | Cost-effectiveness analysis of encorafenib and binimetinib combination as first-line treatment for metastatic or unresectable BRAF V600-mutated metastatic melanoma in Russia | Abstract similar documents |
| N. A. Avxentyev, Yu. V. Makarova | ||
| "... Objective: to perform a cost-effectiveness analysis of using encorafenib and binimetinib ..." | ||
| Vol 15, No 1 (2022) | Pharmacoeconomic analysis of using Monofer in patients with iron deficiency anemia as part of the provision of medical care under the state guarantees program in the health care system of the Russian Federation | Abstract similar documents |
| R. I. Yagudina, A. Yu. Kulikov, V. G. Serpik, O. A. Gromova, I. Yu. Torshin | ||
| "... , costs and costeffectiveness. Comparison of preparations of oligoisomaltose iron [III] (Monofer ..." | ||
| Vol 13, No 3 (2020) | Regulatory framework of the oncological medical care provision | Abstract similar documents |
| S. N. Tishkina, V. E. Matskevich, Yu. A. Ledovskikh, E. V. Semakova, V. V. Omelyanovskiy | ||
| Vol 15, No 1 (2022) | Cost-effectiveness and budget impact analyses of using implantable cardioverter-defibrillators in the Russian Federation | Abstract similar documents |
| T. O. Bessonova, F. V. Gorkavenko, D. G. Shchurov, Yu. V. Seryapina, O. R. Chetverikova, V. V. Omelyanovskiy, S. N. Krivolapov, N. M. Neminushchiy, A. A. Kalemberg | ||
| "... Objective: to evaluate cost-effectiveness and budget impact of using single and dual chamber ..." | ||
| Vol 5, No 2 (2012) | PHARMACOECONOMIC STUDY OF PRIMARY OPEN-ANGLE GLAUCOMA TREATMENT WITH COMBINATIONS OF PROSTAGLANDIN ANALOGUES AND BETA-BLOCKERS | Abstract similar documents |
| A. Yu. Kulikov, V. G. Serpikov | ||
| "... analogues and beta-blockers by mean of cost-efficacy and budget impact analysis. Results have shown ..." | ||
| Vol 8, No 4 (2015) | CLINICAL AND ECONOMIC EVALUATION OF THROMBOPOIETIN RECEPTOR AGONISTS IN THE TREATMENT OF CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA IN ADULTS | Abstract similar documents |
| E. A. Pyadushkina, M. Yu. Frolov, M. V. Avksentyeva | ||
| "... for the cost-minimization analysis (model 1) and analysis of the budget impact TRA usage (model 2 ..." | ||
| Vol 10, No 1 (2017) | PERAMPANEL EFFECTIVENESS IN THE TREATMENT OF REFRACTERY PARTIAL ONSET EPILEPSY WITH OR WITHOUT SECONDARY GENERALIZATION: PHARMACOECONOMIC ANALYSIS FOR THE RUSSIAN FEDERATION HEALTH CARE SYSTEM | Abstract similar documents |
| N. K. Mazina, I. V. Sheshunov, P. V. Мazin, Yu. V. Kislitsin, E. M. Markova | ||
| "... of perampanel and it`s clinical stability in patients at different dosing regimens, and evaluate the cost ..." | ||
| Vol 16, No 3 (2023) | Comparative analysis of using atezolizumab vs. durvalumab in combination with platinum-containing chemotherapy in adult patients with advanced small cell lung cancer | Abstract similar documents |
| I. S. Krysanov, E. V. Makarova, V. Yu. Ermakova | ||
| "... . Objective: to evaluate the clinical and cost-effectiveness of using ATZ and Durv as first-line therapy ..." | ||
| Vol 16, No 2 (2023) | Pharmacoeconomic analysis of tixagevimab and cilgavimab combination for COVID-19 therapy | Abstract similar documents |
| M. V. Zhuravleva, V. P. Chulanov, Yu. V. Gagarina, E. A. Shabalina | ||
| "... of costs and outcomes were used for patients with COVID-19 and post-COVID-19 syndrome, respectively ..." | ||
| Vol 16, No 2 (2023) | Сlinical and economic evaluation of various etiotropic chemotherapy regimens in patients with respiratory tuberculosis with multidrug and extensively drug resistance | Abstract similar documents |
| N. Yu. Nikolenko, D. A. Kudlay, S. E. Borisov, T. E. Sannikova, N. P. Doktorova | ||
| "... costeffectiveness analysis and pharmacoeconomic modeling were used. When assessing the economic costs of treatment ..." | ||
| Vol 16, No 4 (2023) | Socio-economic burden of respiratory syncytial viral infection of the lower respiratory tract in children aged from birth to 5 years in the Russian Federation: modeling results | Abstract similar documents |
| V. I. Ignatyeva, D. Yu. Ovsyannikov, A. E. Tsygankov, E. E. Yagnenkova, V. R. Amirova, M. M. Maryanyan, A. S. Mokrova | ||
| "... months, 12 – <24 months, and 24 – 60 months. The costs of medical care were determined according ..." | ||
| Vol 6, No 4 (2013) | Pharmacoeconomic analysis of blood glucose meter Contour TS in diabetes treatment | Abstract similar documents |
| A. U. Kulikov, V. V. Babiy | ||
| "... influence on the cost and effectiveness of diabetes and its complications treatment. This pharmacoeconomic ..." | ||
| Vol 16, No 2 (2023) | Comparative pharmacoeconomic analysis of follitropin delta application for superovulation induction during artificial insemination | Abstract similar documents |
| I. S. Krysanov, V. S. Krysanova, V. Yu. Ermakova | ||
| "... )), the cost-effectiveness analysis was used. The cost analysis included only direct medical costs: drugs ..." | ||
| 1 - 45 of 45 Items | ||
Search tips:
- Search terms are case-insensitive
- Common words are ignored
- By default articles containing any term in the query are returned (i.e., OR is implied)
- Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
- Combine multiple words with AND to find articles containing all terms; e.g., education AND research
- Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
- Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
- Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)
